Filing Details

Accession Number:
0001214659-22-010296
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-16 16:15:53
Reporting Period:
2022-08-12
Accepted Time:
2022-08-16 16:15:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1225503 A L Bruce Carter C/O Mirati Therapeutics, Inc
3545 Cray Court
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-12 10,000 $27.00 16,021 No 4 M Direct
Common Stock Disposition 2022-08-12 5,107 $85.04 10,914 No 4 S Direct
Common Stock Disposition 2022-08-12 4,893 $85.96 6,021 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non Qualified Stock Option (right to buy) Disposition 2022-08-12 10,000 $0.00 10,000 $27.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2028-01-17 No 4 M Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $84.55 to $85.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices ranging from $85.60 to $86.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The shares subject to the Option vested and became exercisable in 12 equal monthly installments following the date of grant.